133 related articles for article (PubMed ID: 33512408)
1. TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target.
Kennedy E; Coulter E; Halliwell E; Profitos-Peleja N; Walsby E; Clark B; Phillips EH; Burley TA; Mitchell S; Devereux S; Fegan CD; Jones CI; Johnston R; Chevassut T; Schulz R; Seiffert M; Agathanggelou A; Oldreive C; Davies N; Stankovic T; Liloglou T; Pepper C; Pepper AGS
Blood; 2021 Jun; 137(22):3064-3078. PubMed ID: 33512408
[TBL] [Abstract][Full Text] [Related]
2. Chronic lymphocytic leukemia cells acquire regulatory B-cell properties in response to TLR9 and CD40 activation.
Ringelstein-Harlev S; Avivi I; Fanadka M; Horowitz NA; Katz T
Cancer Immunol Immunother; 2018 May; 67(5):739-748. PubMed ID: 29450641
[TBL] [Abstract][Full Text] [Related]
3. BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor.
Ozer HG; El-Gamal D; Powell B; Hing ZA; Blachly JS; Harrington B; Mitchell S; Grieselhuber NR; Williams K; Lai TH; Alinari L; Baiocchi RA; Brinton L; Baskin E; Cannon M; Beaver L; Goettl VM; Lucas DM; Woyach JA; Sampath D; Lehman AM; Yu L; Zhang J; Ma Y; Zhang Y; Spevak W; Shi S; Severson P; Shellooe R; Carias H; Tsang G; Dong K; Ewing T; Marimuthu A; Tantoy C; Walters J; Sanftner L; Rezaei H; Nespi M; Matusow B; Habets G; Ibrahim P; Zhang C; Mathé EA; Bollag G; Byrd JC; Lapalombella R
Cancer Discov; 2018 Apr; 8(4):458-477. PubMed ID: 29386193
[TBL] [Abstract][Full Text] [Related]
4. Siglec-6 as a therapeutic target for cell migration and adhesion in chronic lymphocytic leukemia.
Nunes J; Tafesse R; Mao C; Purcell M; Mo X; Zhang L; Long M; Cyr MG; Rader C; Muthusamy N
Nat Commun; 2024 Jun; 15(1):5180. PubMed ID: 38890323
[TBL] [Abstract][Full Text] [Related]
5. IκBε deficiency accelerates disease development in chronic lymphocytic leukemia.
Bordini J; Lenzi C; Frenquelli M; Morabito A; Pseftogas A; Belloni D; Mansouri L; Tsiolas G; Perotta E; Ranghetti P; Gandini F; Genova F; Hägerstrand D; Gavriilidis G; Keisaris S; Pechlivanis N; Davi F; Kay NE; Langerak AW; Pospisilova S; Scarfò L; Makris A; Psomopoulos FE; Stamatopoulos K; Rosenquist R; Campanella A; Ghia P
Leukemia; 2024 Jun; 38(6):1287-1298. PubMed ID: 38575671
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic Insights into CpG DNA and IL-15 Synergy in Promoting B Cell Chronic Lymphocytic Leukemia Clonal Expansion.
Gupta R; Yan XJ; Barrientos J; Kolitz JE; Allen SL; Rai K; Chiorazzi N; Mongini PKA
J Immunol; 2018 Sep; 201(5):1570-1585. PubMed ID: 30068596
[TBL] [Abstract][Full Text] [Related]
7. Proliferative Signals in Chronic Lymphocytic Leukemia; What Are We Missing?
Haselager MV; Kater AP; Eldering E
Front Oncol; 2020; 10():592205. PubMed ID: 33134182
[TBL] [Abstract][Full Text] [Related]
8. Mouse models of CLL: In vivo modeling of disease initiation, progression, and transformation to Richter transformation.
Chen SS
Semin Hematol; 2024 Apr; ():. PubMed ID: 38755077
[TBL] [Abstract][Full Text] [Related]
9. Massively recruited sTLR9
Kou M; Lu W; Zhu M; Qu K; Wang L; Yu Y
Cancer Immunol Immunother; 2023 Aug; 72(8):2671-2686. PubMed ID: 37079065
[TBL] [Abstract][Full Text] [Related]
10. Kennedy E, Coulter E, Halliwell E, et al. TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target. Blood. 2021;137(22):3064-3078.
Blood; 2024 Jan; 143(1):93. PubMed ID: 38175675
[No Abstract] [Full Text] [Related]
11. EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4
Roessner PM; Llaó Cid L; Lupar E; Roider T; Bordas M; Schifflers C; Arseni L; Gaupel AC; Kilpert F; Krötschel M; Arnold SJ; Sellner L; Colomer D; Stilgenbauer S; Dietrich S; Lichter P; Izcue A; Seiffert M
Leukemia; 2021 Aug; 35(8):2311-2324. PubMed ID: 33526861
[TBL] [Abstract][Full Text] [Related]
12. Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1.
Kohlhaas V; Blakemore SJ; Al-Maarri M; Nickel N; Pal M; Roth A; Hövelmeyer N; Schäfer SC; Knittel G; Lohneis P; Nikolic M; Wiederstein JL; Franitza M; Georgomonolis T; Reinart N; Herling M; Herling C; Hartmann EM; Rosenwald A; Klapper W; Büttner R; Moia R; Rossi D; Boldorini R; Gaidano G; Frenzel LP; Reinhardt HC; Brüning JC; Hallek M; Krüger M; Peifer M; Pallasch CP; Wunderlich FT
Blood; 2021 Feb; 137(5):646-660. PubMed ID: 33538798
[TBL] [Abstract][Full Text] [Related]
13. Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families.
Slager SL; Lanasa MC; Marti GE; Achenbach SJ; Camp NJ; Abbasi F; Kay NE; Vachon CM; Cerhan JR; Johnston JB; Call TG; Rabe KG; Kleinstern G; Boddicker NJ; Norman AD; Parikh SA; Leis JF; Banerji V; Brander DM; Glenn M; Ferrajoli A; Curtin K; Braggio E; Shanafelt TD; McMaster ML; Weinberg JB; Hanson CA; Caporaso NE
Blood; 2021 Apr; 137(15):2046-2056. PubMed ID: 33512457
[TBL] [Abstract][Full Text] [Related]
14. Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy.
Kretzmer H; Biran A; Purroy N; Lemvigh CK; Clement K; Gruber M; Gu H; Rassenti L; Mohammad AW; Lesnick C; Slager SL; Braggio E; Shanafelt TD; Kay NE; Fernandes SM; Brown JR; Wang L; Li S; Livak KJ; Neuberg DS; Klages S; Timmermann B; Kipps TJ; Campo E; Gnirke A; Wu CJ; Meissner A
Blood Cancer Discov; 2021 Jan; 2(1):54-69. PubMed ID: 33604581
[TBL] [Abstract][Full Text] [Related]
15. Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication.
Lu P; Wang S; Franzen CA; Venkataraman G; McClure R; Li L; Wu W; Niu N; Sukhanova M; Pei J; Baldwin DA; Nejati R; Wasik MA; Khan N; Tu Y; Gao J; Chen Y; Ma S; Larson RA; Wang YL
Blood Cancer J; 2021 Feb; 11(2):39. PubMed ID: 33602908
[TBL] [Abstract][Full Text] [Related]
16. Overcoming resistance to targeted therapies in chronic lymphocytic leukemia.
Skånland SS; Mato AR
Blood Adv; 2021 Jan; 5(1):334-343. PubMed ID: 33570649
[TBL] [Abstract][Full Text] [Related]
17. B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide.
Fürstenau M; Fink AM; Schilhabel A; Weiss J; Robrecht S; Eckert R; de la Serna J; Crespo M; Coscia M; Vitale C; Böttcher S; Weppner G; Ritgen M; Stilgenbauer S; Tausch E; Fischer K; Hallek M; Eichhorst B; Brüggemann M; Herling CD
Blood; 2021 Apr; 137(16):2267-2271. PubMed ID: 33512465
[No Abstract] [Full Text] [Related]
18. ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models.
Vaisitti T; Arruga F; Vitale N; Lee TT; Ko M; Chadburn A; Braggio E; Di Napoli A; Iannello A; Allan JN; Miller LL; Lannutti BJ; Furman RR; Jessen KA; Deaglio S
Blood; 2021 Jun; 137(24):3365-3377. PubMed ID: 33512452
[TBL] [Abstract][Full Text] [Related]
19. Mapping comorbidity in chronic lymphocytic leukemia: impact of individual comorbidities on treatment, mortality, and causes of death.
Rotbain EC; Niemann CU; Rostgaard K; da Cunha-Bang C; Hjalgrim H; Frederiksen H
Leukemia; 2021 Sep; 35(9):2570-2580. PubMed ID: 33603143
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
